Loyal portfolio

Insybio logo

Insybio

Healthcare / Medical / Biomed · USA

Follow OnUSAINSEADSDG 3
Konstantinos TheofilatosL

Konstantinos Theofilatos · Labros Digonis

About Insybio

We drive innovation in both clinical trials and drug discovery and, through our proprietary AI empowered platform, are a leading company in targeted biomarker discovery for fields such as Cancer, Nutrition, Infectious and Neurodegenerative diseases. Through this we enable precision medicine.

Visit website

In the news

  • Oct 12

    InSyBio recaps its Python workshop, guiding researchers through mass-spectrometry and multi-omics analysis workflows.

    View on LinkedIn
  • Oct 4

    InSyBio offers focused bioinformatics analyses, including RNA-seq, proteomics, biomarker discovery, and data preparation.

    Read more
  • Oct 4

    InSyBio offers scoped support for omics analysis tasks, including biomarker modeling, pathway enrichment, and data cleaning.

    Read more
  • Oct 3

    InSyBio highlights how focused external analysis support can help research teams advance well-defined datasets or questions.

    Read more
  • Oct 3

    InSyBio offers scoped support for omics analysis, from data cleaning to biomarker modeling.

    Read more
  • Oct 3

    InSyBio advises mapping gene identifiers before comparing expression, running enrichment, or integrating datasets.

    View on LinkedIn

Founders

  • Konstantinos Theofilatos

    Konstantinos Theofilatos

  • L

    Labros Digonis

Details

Stage
Follow On
Sector
Healthcare / Medical / Biomed, AI / Machine Learning
Country
USA
Region
USA
Source
INSEAD
UN SDGs
SDG 3